Frontiers in Oncology · 2022 · 12 citations · 24 references
PharmacyOncologyPharmacoeconomicsChemotherapyCost-effectiveness AnalysisPharmacoeconomic ModelingChemotherapy Dose CalculationConcurrent ChemoradiationCost-effectiveness ModelingCost-effectiveness ThresholdsOutcome ValuationWillingness-to-pay ThresholdsCancer Cost BurdenCapecitabine-based TherapyCost-effectivenessEconomic Burden Of CancerHealth Outcomes AnalysisIncremental Cost EstimationMarkov Cost-effectiveness ModelsModel Robustness Assessment
Background: Adding metronomic capecitabine to concurrent chemoradiotherapy (CCRT) brings failure-free survival (FFS) benefits to patients with locoregionally advanced nasopharyngeal carcinoma (NPC). This study assesses the cost-effectiveness of metronomic capecitabine in locoregionally advanced NPC. Methods: We created a Markov model to calculate the expense and health outcomes of metronomic capecitabine compared to those observed in locoregionally advanced NPC. Related costs, like life-years (LYs), quality-adjusted life years (QALYs), and incremental cost-effective ratios (ICERs) were measured at a willingness-to-pay (WTP) threshold of $33,585 per QALY. A combination of different sensitivity analyses was used to test for model robustness. Additionally, a subgroup analysis was also performed. Results: In contrast to what is observed in the locoregionally advanced NPC, adding the metronomic adjuvant capecitabine yielded an additional 1.11 QALYs with an incremental cost of $10,741.59, which obtained an ICER of $9,669.99 per QALY. The result of one-way sensitive analysis indicated that the utility of FFS, progression disease (PD), and the cost of follow-up were the most significant factors. The probability of metronomic capecitabine being cost-effective was 97.1% at a WTP of $33,585 per QALY. Conclusion: Metronomic capecitabine as adjuvant chemotherapy is a cost-effective strategy for locoregionally advanced NPC patients.
24
Ying Sun, Wen-Fei Li, Nian-Yong Chen et al. · The Lancet Oncology · 2016 · 950 citations
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
Yuan Zhang, Lei Chen, Guoqing Hu et al. · New England Journal of Medicine · 2019 · 935 citations · Full text
Medicine, Oncology, Chemotherapy +11
Lei Chen, Chaosu Hu, Xiao-Zhong Chen et al. · The Lancet Oncology · 2011 · 564 citations